checkAd

     649  0 Kommentare Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO

    STOCKHOLM, Oct. 20, 2018 /PRNewswire/ -- The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose

    • Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease
    • 10 mg/kg currently investigated before start of phase IIa during Q4 2018

    Cantargia AB (publ) today presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 (nidanilimab) in a poster presentation at the ESMO Congress 2018 in Munich, Germany. Data from 16 patients with advanced cancer treated with weekly infusions between 1 mg/kg and 6 mg/kg were presented.

    The poster presentation – with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors­ – was given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. The poster is available on Cantargia's website, www.cantargia.com.

    The presentation included data from the cutoff date, October 5, 2018, on 16 heavily pretreated patients with advanced colorectal cancer (9), non-small cell lung cancer (3) or pancreatic cancer (4) treated with weekly infusions at escalating dose levels from 1 mg/kg to 6 mg/kg. Prior to CAN04, the patients had received an average of 4 different cancer therapies.

    The most common side effects of CAN04 were infusion related reactions and related events, such as nausea, fatigue and fever. These side effects were generally associated with the first dose and were reversible. It can be concluded that 6 mg/kg is a safe dose and the maximum tolerated dose of CAN04 is higher. The trial is now investigating treatment at 10 mg/kg of CAN04 before moving into phase IIa.

    "I am very pleased with the results obtained so far. CAN04 has generally been well tolerated using repeated dosing. The good safety profile and initial effects are encouraging and supportive for the next step in the trial, which is combination with chemotherapy", said Prof. Ahmad Awada, the coordinating investigator of the CANFOUR trial.

    The initial biomarker analysis shows that the serum levels of IL-6 were reduced in 11 out of 14 patients after two weeks and serum levels of CRP were reduced in 9 out of 11 patients with available samples. Levels of IL-6 and CRP are often increased in cancer patients and are associated with disease progression. Preliminary efficacy results show that five patients achieved stable disease, eight progressed and three could not be evaluated. One patient with NSCLC had stable disease for six months.

    Seite 1 von 3



    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO STOCKHOLM, Oct. 20, 2018 /PRNewswire/ - The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease 10 mg/kg currently investigated before start of phase IIa during …